Advertisement

Role of Immunoglobulin Therapy to Prevent and Treat Infections

  • Aspasia Katragkou
  • Emmanuel Roilides
  • Thomas J. Walsh
Chapter

Abstract

Immunoglobulins have been used widely in medicine for a variety of diseases including infectious diseases. While the main clinical applications of immunoglobulin therapy concern their use as replacement for patients with primary immunodeficiencies, or as treatment for autoimmune and inflammatory disorders, their role in infectious disease is limited largely to viral and toxin neutralization and replacement therapy in patients with immunoglobulin deficiencies. Many aspects of the therapeutic regimen of immunoglobulins even in the established indications remain open. Recently, due to the worldwide surge of immunosuppression caused by AIDS, organ transplantation, cancer, and autoimmune therapies, as well as the emergence of multidrug-resistant bacteria, there has been renewed interest in the use of antibody preparation to prevent infections in high-risk groups.

Knowing the limitations of the current anti-infective armamentarium, approaches that target the host through manipulations to augment the host immune response provide a helpful aid to conventional treatment options. A substantial body of evidence has demonstrated that strategies aiming to support or stimulate immune response could be feasible approaches that would benefit immunocompromised patients. In the present chapter, we present contemporary indications of immunoglobulin administration for therapy and prophylaxis of infections in the immunocompromised population.

Keywords

Immunodeficiency Transplantation Autoimmune Monoclonal Antibody Immunization Sepsis Serum 

References

  1. 1.
    Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant. 1999;23(9):929–32.  https://doi.org/10.1038/sj.bmt.1701742.CrossRefPubMedGoogle Scholar
  2. 2.
    Abolhassani H, Asgardoon MH, Rezaei N, Hammarstrom L, Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol. 2015;11(11):1229–43.  https://doi.org/10.1586/1744666X.2015.1079485.CrossRefPubMedGoogle Scholar
  3. 3.
    Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47.  https://doi.org/10.1001/jama.290.2.238.CrossRefPubMedGoogle Scholar
  4. 4.
    Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273(12):934–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090.  https://doi.org/10.1002/14651858.CD001090.CrossRefGoogle Scholar
  6. 6.
    Almansa R, Tamayo E, Andaluz-Ojeda D, Nogales L, Blanco J, Eiros JM, et al. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care. 2015;19:90.  https://doi.org/10.1186/s13054-015-0793-0.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA. 2000;283(13):1723–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–51.  https://doi.org/10.1056/NEJMra1208623.CrossRefPubMedGoogle Scholar
  10. 10.
    Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158(Suppl 1):14–22.  https://doi.org/10.1111/j.1365-2249.2009.04023.x.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 1993;12(3):273–82.PubMedGoogle Scholar
  12. 12.
    Berger M. Goals of therapy in antibody deficiency syndromes. J Allergy Clin Immunol. 1999;104(5):911–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28(2):413–37., x.  https://doi.org/10.1016/j.iac.2008.01.008.CrossRefGoogle Scholar
  14. 14.
    Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care. 2012;27(2):167–71.  https://doi.org/10.1016/j.jcrc.2011.05.012.CrossRefPubMedGoogle Scholar
  15. 15.
    Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336(13):912–8.  https://doi.org/10.1056/NEJM199703273361303.CrossRefPubMedGoogle Scholar
  16. 16.
    Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol. 2013;33(Suppl 2):S90–4.  https://doi.org/10.1007/s10875-012-9838-1.CrossRefPubMedGoogle Scholar
  17. 17.
    Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–2.  https://doi.org/10.1016/j.jaci.2008.04.044.CrossRefPubMedGoogle Scholar
  18. 18.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653–8.  https://doi.org/10.1056/NEJM198709103171101.CrossRefPubMedGoogle Scholar
  19. 19.
    Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314(16):1006–10.  https://doi.org/10.1056/NEJM198604173141602.CrossRefPubMedGoogle Scholar
  20. 20.
    Brockson ME, Novotny LA, Mokrzan EM, Malhotra S, Jurcisek JA, Akbar R, et al. Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms. Mol Microbiol. 2014;93(6):1246–58.  https://doi.org/10.1111/mmi.12735.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–8.PubMedGoogle Scholar
  22. 22.
    Caccavelli L, Field AC, Betin V, Dreillard L, Belair MF, Bloch MF, et al. Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells. Eur J Immunol. 2001;31(9):2781–90.  https://doi.org/10.1002/1521-4141(200109)31:9<2781. AID-IMMU2781>3.0.CO;2-ZCrossRefPubMedGoogle Scholar
  23. 23.
    Casadei DH, CRM D, Opelz G, Golberg JC, Argento JA, Greco G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation. 2001;71(1):53–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703.  https://doi.org/10.1038/nrmicro974.CrossRefPubMedGoogle Scholar
  25. 25.
    Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24(9):474–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Casadevall A, Pirofski LA. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol. 2006;91:1–44.  https://doi.org/10.1016/S0065-2776(06)91001-3.CrossRefPubMedGoogle Scholar
  27. 27.
    Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38(8):1695–702.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol. 1994;88(1):209–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996;24(9):1431–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Condie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am J Med. 1984;76(3A):134–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Condino-Neto A, Costa-Carvalho BT, Grumach AS, King A, Bezrodnik L, Oleastro M, et al. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol (Madr). 2014;42(3):245–60.  https://doi.org/10.1016/j.aller.2012.09.006.CrossRefGoogle Scholar
  33. 33.
    Cottler-Fox M, Lynch M, Pickle LW, Cahill R, Spitzer TR, Deeg HJ. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant. 1991;8(1):27–33.PubMedGoogle Scholar
  34. 34.
    Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med. 2003;138(6):502–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin Exp Immunol. 2011;164(Suppl 2):16–9.  https://doi.org/10.1111/j.1365-2249.2011.04390.x.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.  https://doi.org/10.1007/s00134-012-2769-8.CrossRefPubMedGoogle Scholar
  37. 37.
    Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med. 1995;23(9):1461–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, et al. Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol. 2009;158(Suppl 1):2–13.  https://doi.org/10.1111/j.1365-2249.2009.04022.x.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109(10):777–82.CrossRefPubMedGoogle Scholar
  40. 40.
    Feinstein LC, Seidel K, Jocum J, Bowden RA, Anasetti C, Deeg HJ, et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant. 1999;5(6):369–78.CrossRefPubMedGoogle Scholar
  41. 41.
    Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–56.  https://doi.org/10.1056/NEJMoa040232.CrossRefPubMedGoogle Scholar
  42. 42.
    Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993;21(3):318–27.CrossRefPubMedGoogle Scholar
  43. 43.
    Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med. 1913;17(5):553–76.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Goodman SD, Obergfell KP, Jurcisek JA, Novotny LA, Downey JS, Ayala EA, et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol. 2011;4(6):625–37.  https://doi.org/10.1038/mi.2011.27.CrossRefPubMedGoogle Scholar
  45. 45.
    Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015;10(3):129–34.  https://doi.org/10.1097/COH.0000000000000154.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant. 1988;3(6):559–66.PubMedGoogle Scholar
  47. 47.
    Grass G, Neugebauer EA. Afelimomab-another therapeutic option in sepsis therapy? Crit Care Med. 2004;32(11):2343–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Group IC, Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365(13):1201–11.  https://doi.org/10.1056/NEJMoa1100441.CrossRefGoogle Scholar
  49. 49.
    Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant. 1994;13(5):499–510.PubMedGoogle Scholar
  50. 50.
    Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158(Suppl 1):23–33.  https://doi.org/10.1111/j.1365-2249.2009.04024.x.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34(5):1319–25.  https://doi.org/10.1097/01.CCM.0000215452.84291.C6.CrossRefPubMedGoogle Scholar
  52. 52.
    Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228–31.CrossRefPubMedGoogle Scholar
  53. 53.
    The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325(2):73–80.  https://doi.org/10.1056/NEJM199107113250201.
  54. 54.
    Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902–7.  https://doi.org/10.1056/NEJM198810063191403.
  55. 55.
    Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2 Pt A):171–82.  https://doi.org/10.1016/j.molimm.2015.03.255.CrossRefPubMedGoogle Scholar
  56. 56.
    Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787–94.  https://doi.org/10.1001/jama.2010.1553.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Jenson HB, Pollock BH. The role of intravenous immunoglobulin for the prevention and treatment of neonatal sepsis. Semin Perinatol. 1998;22(1):50–63.CrossRefPubMedGoogle Scholar
  58. 58.
    Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66(6):800–5.CrossRefPubMedGoogle Scholar
  59. 59.
    Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant. 2011;11(2):196–202.  https://doi.org/10.1111/j.1600-6143.2010.03400.x.CrossRefPubMedGoogle Scholar
  60. 60.
    Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation. 2009;88(1):1–6.  https://doi.org/10.1097/TP.0b013e3181a9e89a.CrossRefPubMedGoogle Scholar
  61. 61.
    Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15(12):3256–62.  https://doi.org/10.1097/01.ASN.0000145878.92906.9F.CrossRefPubMedGoogle Scholar
  62. 62.
    Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–14.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26(6):813–27.  https://doi.org/10.1592/phco.26.6.813.CrossRefPubMedGoogle Scholar
  65. 65.
    Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35(12):2677–85.PubMedGoogle Scholar
  66. 66.
    Laupland KB, Boucher P, Rotstein C, Cook DJ, Doig CJ. Intravenous immunoglobulin for severe infections: a survey of Canadian specialists. J Crit Care. 2004;19(2):75–81.CrossRefPubMedGoogle Scholar
  67. 67.
    Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35(12):2686–92.PubMedGoogle Scholar
  68. 68.
    Lindenmann J. Origin of the terms ‘antibody’ and ‘antigen’. Scand J Immunol. 1984;19(4):281–5.CrossRefPubMedGoogle Scholar
  69. 69.
    Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992;14(4):831–5.CrossRefPubMedGoogle Scholar
  70. 70.
    Llewelyn MB, Hawkins RE, Russell SJ. Discovery of antibodies. BMJ. 1992;305(6864):1269–72.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195–203.  https://doi.org/10.1016/j.molmed.2014.01.007.CrossRefPubMedGoogle Scholar
  72. 72.
    Mofenson LM, Moye J Jr, Korelitz J, Bethel J, Hirschhorn R, Nugent R. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J. 1994;13(6):477–84.PubMedGoogle Scholar
  73. 73.
    Moss M. Epidemiology of sepsis: race, sex, and chronic alcohol abuse. Clin Infect Dis. 2005;41(Suppl 7):S490–7.  https://doi.org/10.1086/432003.CrossRefPubMedGoogle Scholar
  74. 74.
    Nahirniak S, Hume HA. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev. 2010;24(Suppl 1):S1–6.  https://doi.org/10.1016/j.tmrv.2009.09.009.CrossRefPubMedGoogle Scholar
  75. 75.
    Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care. 2005;20(3):239–49.  https://doi.org/10.1016/j.jcrc.2005.03.003.CrossRefPubMedGoogle Scholar
  76. 76.
    Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008a;26:513–33.  https://doi.org/10.1146/annurev.immunol.26.021607.090232.CrossRefPubMedGoogle Scholar
  77. 77.
    Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008b;8(1):34–47.  https://doi.org/10.1038/nri2206.CrossRefPubMedGoogle Scholar
  78. 78.
    Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260(6):509–16.  https://doi.org/10.1111/j.1365-2796.2006.01726.x.CrossRefPubMedGoogle Scholar
  79. 79.
    Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004a;1:CD000361.  https://doi.org/10.1002/14651858.CD000361.pub2.CrossRefGoogle Scholar
  80. 80.
    Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004b;1:CD001239.  https://doi.org/10.1002/14651858.CD001239.pub2.CrossRefGoogle Scholar
  81. 81.
    Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013a;7:CD000361.  https://doi.org/10.1002/14651858.CD000361.pub3.CrossRefGoogle Scholar
  82. 82.
    Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2013b;7:CD001239.  https://doi.org/10.1002/14651858.CD001239.pub4.CrossRefGoogle Scholar
  83. 83.
    Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2015;3:CD001239.  https://doi.org/10.1002/14651858.CD001239.pub5.CrossRefGoogle Scholar
  84. 84.
    Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.  https://doi.org/10.1016/j.jaci.2006.01.015.CrossRefPubMedGoogle Scholar
  85. 85.
    Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32(11):2173–82.CrossRefPubMedGoogle Scholar
  86. 86.
    Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014;6(7):853–69.  https://doi.org/10.2217/imt.14.54.CrossRefPubMedGoogle Scholar
  87. 87.
    Petersen FB, Bowden RA, Thornquist M, Meyers JD, Buckner CD, Counts GW, et al. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant. 1987;2(2):141–7.PubMedGoogle Scholar
  88. 88.
    Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39(1):38–46.  https://doi.org/10.1086/421089.CrossRefPubMedGoogle Scholar
  89. 89.
    Pilz G, Appel R, Kreuzer E, Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest. 1997;111(2):419–26.CrossRefPubMedGoogle Scholar
  90. 90.
    Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;4:CD006501.  https://doi.org/10.1002/14651858.CD006501.pub2.CrossRefGoogle Scholar
  91. 91.
    Riechsteiner G, Speich R, Schanz U, Russi EW, Weder W, Boehler A. Haemolytic anaemia after lung transplantation: an immune-mediated phenomenon? Swiss Med Wkly. 2003;133(9–10):143–7. doi:2003/09/smw-10123PubMedGoogle Scholar
  92. 92.
    Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–89.  https://doi.org/10.1038/nri3401.CrossRefPubMedGoogle Scholar
  93. 93.
    Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis – biological plausibility from a critical care perspective. Crit Care. 2012;16(2):206.  https://doi.org/10.1186/cc10597.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S7–S27.  https://doi.org/10.1016/j.tmrv.2009.09.010.CrossRefPubMedGoogle Scholar
  95. 95.
    Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994;331(18):1181–7.  https://doi.org/10.1056/NEJM199411033311802.CrossRefPubMedGoogle Scholar
  96. 96.
    Stiehm ER, Ashida E, Kim KS, Winston DJ, Haas A, Gale RP. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med. 1987;107(3):367–82.CrossRefPubMedGoogle Scholar
  97. 97.
    Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr Infect Dis. 2010;57(1):185–218.  https://doi.org/10.1016/j.yapd.2010.08.005.CrossRefGoogle Scholar
  98. 98.
    Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323(11):705–12.  https://doi.org/10.1056/NEJM199009133231103.CrossRefPubMedGoogle Scholar
  99. 99.
    Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996;2(1):44–53.PubMedGoogle Scholar
  100. 100.
    Taccone FS, Stordeur P, De Backer D, Creteur J, Vincent JL. Gamma-globulin levels in patients with community-acquired septic shock. Shock. 2009;32(4):379–85.  https://doi.org/10.1097/SHK.0b013e3181a2c0b2.CrossRefPubMedGoogle Scholar
  101. 101.
    Ter Meulen J. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin N Am. 2011;25(4):789–802.  https://doi.org/10.1016/j.idc.2011.07.006.CrossRefGoogle Scholar
  102. 102.
    Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29(12):608–15.  https://doi.org/10.1016/j.it.2008.08.004.CrossRefPubMedGoogle Scholar
  103. 103.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.  https://doi.org/10.1016/j.bbmt.2009.06.019.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Trautmann M, Held TK, Susa M, Karajan MA, Wulf A, Cross AS, et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol. 1998;111(1):81–90.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146(3):193–203.CrossRefPubMedGoogle Scholar
  106. 106.
    Valiquette L, Low DE, Chow R, McGeer AJ. A survey of physician's attitudes regarding management of severe group a streptococcal infections. Scand J Infect Dis. 2006;38(11–12):977–82.  https://doi.org/10.1080/00365540600786499.CrossRefPubMedGoogle Scholar
  107. 107.
    Venet F, Gebeile R, Bancel J, Guignant C, Poitevin-Later F, Malcus C, et al. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol. 2011;11(12):2086–90.  https://doi.org/10.1016/j.intimp.2011.08.024.CrossRefPubMedGoogle Scholar
  108. 108.
    Veterans Administration Systemic Sepsis Cooperative Study, G. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317(11):659–65.  https://doi.org/10.1056/NEJM198709103171102.CrossRefGoogle Scholar
  109. 109.
    Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.  https://doi.org/10.1001/jama.2009.1754.CrossRefPubMedGoogle Scholar
  110. 110.
    Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325(2):81–6.  https://doi.org/10.1056/NEJM199107113250202.CrossRefPubMedGoogle Scholar
  111. 111.
    Werdan K. Immunoglobulin treatment in sepsis – is the answer “no”? Crit Care Med. 2006;34(5):1542–4.  https://doi.org/10.1097/01.CCM.0000216189.80613.BB.CrossRefPubMedGoogle Scholar
  112. 112.
    Werdan K. Mirror, mirror on the wall, which is the fairest meta-analysis of all? Crit Care Med. 2007;35(12):2852–4.  https://doi.org/10.1097/01.CCM.0000297164.40980.F0.CrossRefPubMedGoogle Scholar
  113. 113.
    Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007;35(12):2693–701.CrossRefPubMedGoogle Scholar
  114. 114.
    Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017;376(4):305–17.  https://doi.org/10.1056/NEJMoa1602615.CrossRefPubMedGoogle Scholar
  115. 115.
    Winau F, Winau R. Emil von Behring and serum therapy. Microbes Infect. 2002;4(2):185–8.CrossRefPubMedGoogle Scholar
  116. 116.
    Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12(3):283–8.PubMedGoogle Scholar
  117. 117.
    Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106(1):12–8.CrossRefPubMedGoogle Scholar
  118. 118.
    Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med. 1993;118(12):937–42.CrossRefPubMedGoogle Scholar
  119. 119.
    Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol. 1994;97(Suppl 1):59–67.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Stiehm EM, Keller MA. Passive immunization. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al., editors. Textbook of pediatric infectious diseases. 6th ed. Philadelphia: Saunders/Elsevier; 2009. p. 3412–47.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Aspasia Katragkou
    • 1
  • Emmanuel Roilides
    • 2
  • Thomas J. Walsh
    • 1
    • 3
  1. 1.Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Pediatrics, and Microbiology & Immunology, Weill Cornell MedicineHenry Schueler Foundation ScholarNew YorkUSA
  2. 2.Infectious Disease Unit, 3rd Department of Pediatrics, Faculty of MedicineAristotle University School of Health Sciences, Hippokration HospitalThessalonikiGreece
  3. 3.Departments of PediatricsMicrobiology and Immunology Weill Cornell MedicineNew YorkUSA

Personalised recommendations